Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ402 in Diabetic Macular Edema
NCT05712720Phase 2Completed
- Sponsor
- Rezolute, Inc.
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AB402 in diabetic macular edema (DME) (4 arms), sponsored by Rezolute, Inc. Primary endpoint: Central Subfield Thickness at 12 weeks. Started Feb 2023; status: completed.
02
Drugs
AB402
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05712720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712720.